Results 21 to 30 of about 400,612 (318)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease

Alzheimer’s Research & Therapy, 2022
Background Cerebrospinal fluid (CSF) tau and beta-amyloid levels in chronic traumatic encephalopathy (CTE), a disease which can be clinically indistinguishable from Alzheimer’s disease (AD), are largely unknown.
Katherine W. Turk, Alexandra Geada, Victor E. Alvarez, Weiming Xia, Jonathan D. Cherry, Raymond Nicks, Gaoyuan Meng, Sarah Daley, Yorghos Tripodis, Bertrand R. Huber, Andrew E. Budson, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz, Robert A. Stern, Michael L. Alosco, Jesse Mez, Ann C. McKee, Thor D. Stein   +20 more
doaj   +1 more source

Common age‐related neuropathologies and yearly variability in cognition

Annals of Clinical and Translational Neurology, 2019
Objective Cognitive variability is a potentially important source of heterogeneity in longitudinal cognitive profiles. We examined the extent to which common age‐related neuropathologies including Lewy bodies and Alzheimer’s disease (AD) contribute to ...
Lei Yu, Tianhao Wang, Robert S. Wilson, Sue Leurgans, Julie A. Schneider, David A. Bennett, Patricia A. Boyle   +6 more
doaj   +1 more source

Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set

Alzheimer’s Research & Therapy, 2019
Background Longitudinal investigations are needed to improve understanding of the contributions of cerebral small vessel disease to the clinical manifestation of Alzheimer’s disease, particularly in the early disease stages.
Christian Puzo, Caroline Labriola, Michael A. Sugarman, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Thor D. Stein, Neil W. Kowall, Ann C. McKee, Jesse Mez, Ronald J. Killiany, Robert A. Stern, Michael L. Alosco   +13 more
doaj   +1 more source

Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology

Acta Neuropathologica Communications, 2022
Quantification of in vivo amyloid and tau PET imaging relationships with postmortem measurements are critical for validating the sensitivity and specificity imaging biomarkers across clinical phenotypes with Alzheimer disease neuropathologic change (ADNC)
Adam Martersteck, Ivan Ayala, Daniel T. Ohm, Callen Spencer, Christina Coventry, Sandra Weintraub, Eileen H. Bigio, M. -Marsel Mesulam, Changiz Geula, Emily Rogalski   +9 more
doaj   +1 more source

509 Understanding community engagement with research through a curated medical record-based database: A cross-sectional, single site study

Journal of Clinical and Translational Science
Objectives/Goals: Since clinical trial participation is a key translational research initiative, the objectiveis to characterize research participants within a health system using electronic health record (EHR) data and evaluate how community-level ...
Chuan Ching Tsai, Leping Fang, David Sedillo, John Gibbons, Jamie B Plenge, Raj Shah   +5 more
doaj   +1 more source

Communication Bridge™-2 (CB2): an NIH Stage 2 randomized control trial of a speech-language intervention for communication impairments in individuals with mild to moderate primary progressive aphasia

Trials, 2022
Background Primary progressive aphasia (PPA) is a clinical dementia syndrome. Impairments in language (speaking, reading, writing, and understanding) are the primary and persistent symptoms.
Angela C. Roberts, Alfred W. Rademaker, Elizabeth Ann Salley, Aimee Mooney, Darby Morhardt, Melanie Fried-Oken, Sandra Weintraub, Marsel Mesulam, Emily Rogalski   +8 more
doaj   +1 more source

Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice

Journal of Neuroinflammation, 2018
Background Alzheimer’s disease is widely described since the discovery of histopathological lesions in Mrs. Auguste Deter in 1906. However to date, there is no effective treatment to deal with the many cellular and molecular alterations.
J. Vérité, T. Janet, D. Chassaing, B. Fauconneau, H. Rabeony, G. Page   +5 more
doaj   +1 more source

Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase

Experimental and Molecular Medicine, 2020
Age-related neurodegenerative diseases: role of enzyme crucial to membrane function Targeting a critical enzyme involved in the metabolism of cellular membrane molecules could help treat age-related neurodegenerative diseases.
Min Hee Park, Hee Kyung Jin, Jae-sung Bae   +2 more
doaj   +1 more source

ALZHEIMER’S DISEASE PROGNOSIS IS CAPTURED BY A DOWN-UPSIZED INCIDENCE POISSON DISTRIBUTION [PDF]

American Medical Journal, 2013
Alzeimer disease is a daunting nightmare to both the medical and families of the patients. Tireless efforts are made by the medical researchers to treat Alzheimer’s patients. The Alzhiemer patients’ data provides clues about its prognosis and they can be identifies when the data are analyzed and understood correctly.
openaire   +1 more source

Transcriptome analyses of 7-day-old zebrafish larvae possessing a familial Alzheimer’s disease-like mutation in psen1 indicate effects on oxidative phosphorylation, ECM and MCM functions, and iron homeostasis

BMC Genomics, 2021
Background Early-onset familial Alzheimer’s disease (EOfAD) is promoted by dominant mutations, enabling the study of Alzheimer’s disease (AD) pathogenic mechanisms through generation of EOfAD-like mutations in animal models.
Yang Dong, Morgan Newman, Stephen M. Pederson, Karissa Barthelson, Nhi Hin, Michael Lardelli   +5 more
doaj   +1 more source